Abstract
SBRT is a treatment modality for intracranial lesions of oligometastatic NSCLC. Combined with immune checkpoint inhibitors (ICIs), SBRT can improve the anti-tumor effect and the systemic response to immunotherapy via the abscopal effect in brain metastases (BMs) NSCLC patients. Meanwhile, the combination of anlotinib（a novel multi-target tyrosine kinase inhibitor）and ICIs can promote the infiltration of the innate immune cells and conferred potentially synergistic anti-tumor activity. Therefore, triple therapy of SBRT, anlotinib, and toripalimab (anti-PD-1 antibody) may be more effective in driver mutation-negative NSCLC patients with untreated oligometastatic BMs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
